SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009
News Apr 23, 2009
SuperGen Inc. has announced as part of a series of presentations at the 100th Annual Meeting of the American Association for Cancer Research (AACR), that it has identified a new class of small molecules which successfully inhibit Etk/Bmx kinase in preclinical cancer models.
Entitled, “Targeting Etk/Bmx kinase with small molecule inhibitors,” the poster highlights data indicating that SuperGen lead compounds in this class inhibit the autophosphorylation of Etk, the activation of STAT3 downstream of EGF stimulation, and inhibit the colony formation of prostate and liver cancer cells lines in soft agar.
“SuperGen is committed to bringing first in class drugs into the clinic against cancer drug targets, and Etk/Bmx represents another one of these targets,” said Dr. David Bearss, SuperGen’s Chief Scientific Officer. “We are excited about selecting a clinical candidate for this program and think this program signifies another example of what our company and drug discovery technology can accomplish.”
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Pre-Diabetes Discovery Marks Step Towards Precision MedicineNews
Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.READ MORE